249 related articles for article (PubMed ID: 2312106)
21. [Draft of the best medical treatment in patients with low-risk thyroid cancer].
Vlček P; Nováková D; Vejvalka J; Zimák J; Křenek M; Vošmiková K; Smutný S; Bavor P; Astl J; Lukáš J
Vnitr Lek; 2015 Sep; 61(9):769-77. PubMed ID: 26465275
[TBL] [Abstract][Full Text] [Related]
22. [Metastatic differentiated thyroid cancer. Diagnostic accuracy of thyroglobulin-RIA in comparison with 131I-whole body scintigraphy].
Reiners C; Reimann J; Schäffer R; Baum K; Becker W; Eilles C; Gerhards W; Schick F; Spiegel W; Wiedemann W
Rofo; 1984 Sep; 141(3):306-13. PubMed ID: 6435198
[TBL] [Abstract][Full Text] [Related]
23. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
24. Papillary thyroid carcinomas with lung metastases.
Lin JD; Chao TC; Chou SC; Hsueh C
Thyroid; 2004 Dec; 14(12):1091-6. PubMed ID: 15650364
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer.
Qiu ZL; Song HJ; Xu YH; Luo QY
J Clin Endocrinol Metab; 2011 Oct; 96(10):3078-86. PubMed ID: 21795449
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer.
Benbassat CA; Mechlis-Frish S; Hirsch D
World J Surg; 2006 Jun; 30(6):1088-95. PubMed ID: 16736341
[TBL] [Abstract][Full Text] [Related]
27. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
[TBL] [Abstract][Full Text] [Related]
28. The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases.
Mihailovic J; Stefanovic L; Malesevic M; Markoski B
Thyroid; 2009 Mar; 19(3):227-32. PubMed ID: 19265493
[TBL] [Abstract][Full Text] [Related]
29. Papillary and follicular thyroid carcinomas with bone metastases: a series of 39 cases during a period of 18 years.
Fanchiang JK; Lin JD; Huang MJ; Shih HN
Changgeng Yi Xue Za Zhi; 1998 Dec; 21(4):377-82. PubMed ID: 10074721
[TBL] [Abstract][Full Text] [Related]
30. Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component.
Decaussin M; Bernard MH; Adeleine P; Treilleux I; Peix JL; Pugeat M; Tourniaire J; Berger N
Am J Surg Pathol; 2002 Aug; 26(8):1007-15. PubMed ID: 12170087
[TBL] [Abstract][Full Text] [Related]
31. [Non-iodine-absorbing metastasis of differentiated thyroid cancer--therapeutic probe with 13-cis retinoic acid].
Kaniewski M; Czetwertyńska M; Godlewska P; Drac-Kaniewska J
Wiad Lek; 2001; 54 Suppl 1():297-300. PubMed ID: 12182038
[TBL] [Abstract][Full Text] [Related]
32. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
[TBL] [Abstract][Full Text] [Related]
33. Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates.
Tickoo SK; Pittas AG; Adler M; Fazzari M; Larson SM; Robbins RJ; Rosai J
Arch Pathol Lab Med; 2000 Oct; 124(10):1440-7. PubMed ID: 11035572
[TBL] [Abstract][Full Text] [Related]
34. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.
Pace L; Klain M; Albanese C; Salvatore B; Storto G; Soricelli A; Salvatore M
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):179-83. PubMed ID: 16205897
[TBL] [Abstract][Full Text] [Related]
35. Low-Activity Radioactive Iodine Therapy for Thyroid Carcinomas Exhibiting Nodal Metastases and Extrathyroidal Extension May Lead to Early Disease Recurrence.
Chu KP; Baker S; Zenke J; Morad A; Ghosh S; Morrish DW; McEwan AJBS; Williams DC; Severin D; McMullen TPW
Thyroid; 2018 Jul; 28(7):902-912. PubMed ID: 29742993
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
37. Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy.
Qiu ZL; Shen CT; Luo QY
Thyroid; 2015 Feb; 25(2):229-37. PubMed ID: 25331724
[TBL] [Abstract][Full Text] [Related]
38. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
39. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma.
Lubin E; Mechlis-Frish S; Zatz S; Shimoni A; Segal K; Avraham A; Levy R; Feinmesser R
J Nucl Med; 1994 Feb; 35(2):257-62. PubMed ID: 8294995
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.
Zhang XY; Sun JW; Qiu ZL; Wang Y; Chen XY; Zhao JH; Luo QY
Endocrine; 2019 Nov; 66(2):254-265. PubMed ID: 31317522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
